Biopharmaceuticals Derived from Transgenic Plants and Animals

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 3, Issue , 2008, Pages 833-892

  Baez, Julio ^a  

^a FIBROGEN INC   (United States)

Author keywords

Antithrombin; Aprotinin; Glycoprotein; Pulmonary; Transgenic

Indexed keywords

EID: 84889998375     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch35     Document Type: Chapter

References (438)

1. Guide to Biotechnology. 2004. Biotechnology Industry Association www.bio.org.
2. DePalma A. Is a Green Plant in Your Manufacturing Future? BioPharm Int., 2003; 16(11): 24-33.
3. USDA. US Biotech Crop Plantings Fact Sheet -A Precis From The USDA Report. http://usda.mannlib.cornell.edu/reports/nassr/field/pcp-bba/acrg0604.txt 2004.
4. Peterson R, Arntzen CJ. On risk and plantbased biopharmaceuticals. Trends Biotechnol., 2004; 22(2).
5. Denman J, Hayes M, O'Day C, et al. Transgenic expression of a variant of human tissuetype plasminogen activator in goat milk: purification and characterization of the recombinant enzyme. Biotechnology (NY), 1991 ;9(9): 839-843.
6. Barta A. The expression of a nopaline synthase human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue. Plant Mol. Biol., 1986; 6: 347-357.
7. Steiner U. Business Case for Plant Factories. 2003; Plant-Made Pharmaceuticals Conference, Quebec City, Quebec, Canada (on line copy available at http://www.cpmp2003.org/).
8. Baez J. State of the Science: Role of Transgenic Technology in the Biosynthesis of Bio-Pharmaceuticals and Industrial Protein. 2004 (Corn-Produced Pharmaceuticals and Industrials Risk Assessment Symposium, sponsored by the Biosafety Institute for Genetically Modified Agricultural Products Symposium, Ames, Iowa).
9. Behboodi E, Chen M, Destrempes L, et al. Principles of Cloning. Elsevier Science (USA), 2002.
10. Larrick JW, Thomas DW. Producing proteins in transgenic plants and animals. Curr. Opin. Biotechnol., 2001 ;12(4): 411-418.
11. Giddings G, Allison G, Brooks D, et al. Transgenic plants as factories for biopharmaceuticals. Nature Biotechnol., 2000 ;18(11): 1151-1155.
12. Herbers K, Sonnewald U. Production of new/modified proteins in transgenic plants. Curr. Opin. Biotechnol., 1999 ;10(2): 163-168.
13. Okada Y. [Transgenic plants as medicine production systems]. Nippon Yakurigaku Zasshi, 1997; 110 Suppl 1: 1P-6P.
14. Schillberg S, Fischer R, Emans N. Molecular farming of recombinant antibodies in plants. Cell. Mol. Life Sci., 2003 ;60(3): 433-445.
15. Twyman RM, Stoger E, Schillberg S, et al. Molecular farming in plants: host systems and expression technology. Trends Biotechnol., 2003 ;21(12): 570-578.
16. Erickson L, Yu W, Brandle J, et al. (Eds), Molecular farming of plants and animals for human and veterinary medicine. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2002.
17. Cunningham C, Porter A (Eds), Methods in molecular Biology -the production of clinically important recombinant proteins in plants. Totowa, New Jersey, U.S.: Humana Press, 1998.
18. Rohricht P, Ayares D. Transgenic Protein Production: Part 3, Nuclear Transfer Technology. BioPharm, 1999; 56-60.
19. Fischer R, Stoger E, Schillberg S, et al. Plantbased production of biopharmaceuticals. Curr. Opin. Plant Biol., 2004 ;7(2): 152-158.
20. Fischer R, Emans N. Molecular farming of pharmaceutical proteins. Transgenic Res., 2000; 9(4/5): 279-299.
21. Houdebine L. Transgenic animal bioreactors. Transgenic Res., 2000; 9(4/5): 305-320.
22. Giddings G. Transgenic plants as protein factories. Curr. Opin. Biotechnol., 2001 ;12(5): 450-454.
23. Kusnadi A, Nikolov Z, Howard JA. Production of recombinant proteins in transgenic plants: practical considerations. Biotechnol. Bioeng., 1997; 56: 473-484.
24. Horn ME, Woodard SL, Howard JA. Plant molecular farming: systems and products. Plant Cell. Rep., 2004 ;22(10): 711-720.
25. Hood EE, Kusnadi A, Nikolov Z, et al. Molecular farming of industrial proteins from transgenic maize. Adv. Exp. Med. Biol., 1999; 464: 127-147.
26. Langridge WH. Edible vaccines. Sci. Am., 2000 ;283(3): 66-71.
27. Ganz P, Sardana R, Dudani A, et al. In: Owen M, Pen J (Eds), Transgenic Plants: A production system for pharmaceutical proteins. New York: John Wiley and Sons Ltd.; 1996: 281-297.
28. Molecular farming may be next wave for biotech drug manufacturers. January 31, 2003. The Food and Drug Letter Issue, No. 668.
29. Van Brunt J. Molecular Farming Factories. Signals Magazine, Online Magazine of Biotechnology Industry Analysis 2002; http://www.signalsmag.com.
30. Raskin I, Ribnicky DM, Komarnytsky S, et al. Plants and human health in the twenty-first century. Trends Biotechnol., 2002 ;20(12): 522-531.
31. Meni Y, Kovacs J. In: Erickson L, Yu W, Brandle J, et al. (Eds), Molecular Farming of Plants and Animals for Human and Veterinary Medicine. Kluwer Academic; 2002: 287-317.
32. Knäblein J, McCaman M. Modern Biopharmaceuticals -Recombinant Protein Expression in Transgenic Plants. Screening. Trends Drug Discov., 2003; 6: 33-35.
33. Knäblein J. Biotech: A New Era In The New Millennium? Fermentation and Expression of Biopharmaceuticals in Plants. Screening. Trends Drug Discov., 2003; 4: 14-16.
34. Knäblein J. Biopharmaceuticals expressed in plants -a new era in the new Millennium. In: Müller R, Kayser O (Eds), Applications in Pharmaceutical Biotechnology. Wiley-VCH 2004.
35. Knäblein J. Plant-based Expression of Biopharmaceuticals. In: Meyers RE (Ed), Encyclopedia of Molecular Cell Biology and Molecular Medicine. Wiley & Sons, 2005; 2nd edition, Vol. 10: p. 385-410.
36. Stromqvist M, Houdebine L, Andersson J, et al. Recombinant human extracellular superoxide dismutase produced in milk of transgenic rabbits. Transgenic Res., 1997 ;6(4): 271-278.
37. Galet C, Le Bourhis CM, Chopineau M, et al. Expression of a single beta-alpha chain protein of equine LH/CG in milk of transgenic rabbits and its biological activity. Mol. Cell. Endocrinol., 2001; 174(1/2): 31-40.
38. BioProtein Technologies Scientific Publications. http://www.bioprotein.com/gb/news_events.htm#Sequence_1 2004.
39. Transgametic® Process Gala Transgenics. http://www.gala.com/transgametic.html 2004.
40. GTC Biotherapeutics Scientific Publications. http://www.transgenics.com/publications.html 2004.
41. Echelard Y, Meade H. Toward a new cash cow. Nature Biotechnol., 2002 ;20(9): 881-882.
42. Stowers AW, Chen LH, Zhang Y, et al. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci USA, 2002 ;99(1): 339-344.
43. Pollock DP, Kutzko JP, Birck-Wilson E, et al. Transgenic milk as a method for the production of recombinant antibodies. J. Immunol. Methods, 1999; 231(1/2): 147-157.
44. Young MW, Meade H, Curling JM, et al. Production of recombinant antibodies in the milk of transgenic animals. Res. Immunol., 1998 ;149(6): 609-610.
45. Edmunds T, Van Patten SM, Pollock J, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood, 1998 ;91(12): 4561-4571.
46. Ebert KM, Ditullio P, Barry CA, et al. Induction of human tissue plasminogen activator in the mammary gland of transgenic goats. Biotechnology (NY), 1994 ;12(7): 699-702.
47. Ditullio P, Cheng SH, Marshall J, et al. Production of cystic fibrosis transmembrane conductance regulator in the milk of transgenic mice. Biotechnology (NY), 1992 ;10(1): 74-77.
48. Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion, 2003 ;43(3): 390-394.
49. Merrimack Pharmaceuticals Completes Dosing in Phase I Study of Immunomodulator, MM-093. http://www.merrimackpharma.com./news.archive.html#11_19_03 2003.
50. Infigen Transgenic Production Technology. http://www.infigen.com/sci_tech_prot.html 2004.
51. Infigen Terminates Agreement With Pharming Holding, N.V. http://www.biospace.com/ccis/news_story.cfm?StoryID=6578115&full=12001.
52. Niemann H, Halter R, Carnwath J, et al. Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep. Transgenic Res., 1999 ;8(3): 237-347.
53. Ko J, Lee C, Kim K, et al. Production of biologically active human granulocyte colony stimulating factor in the milk of transgenic goat. Transgenic Res., 2000 ;9(3): 215-222.
54. Nexia Biotechnology Fundamental Biology. http://www.nexiabiotech.com/en/03_bio/index.php 2004.
55. Lazaris A, Arcidiacono S, Huang Y, et al. Spider silk fibers spun from soluble recombinant silk produced in mammalian cells. Science, 2002 ;295(5554): 472-476.
56. Pharming Products. http://www.pharming.com/index.php?act=prod 2004.
57. van Berkel PH, Welling MM, Geerts M, et al. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nature Biotechnol., 2002 ;20(5): 484-487.
58. Pharming Features Clinical Results Of C1 Inhibitor At Investigator Meeting. http://www.pharming.com/index.php?act=show&pg=5 2004.
59. PPL Therapeutics Products. http://www.ppltherapeutics. com/products/products.html 2004.
60. Vogel G. Biotechnology. Sheep fail to produce golden fleece. Science, 2003 ;300(5628): 2015-2016.
61. Harris DP, Andrews AT, Wright G, et al. The application of aqueous two-phase systems to the purification of pharmaceutical proteins from transgenic sheep milk. Bioseparation, 1997 ;7(1): 31-37.
62. Chen SH, Vaught TD, Monahan JA, et al. Efficient production of transgenic cloned calves using preimplantation screening. Biol. Reprod., 2002 ;67(5): 1488-1492.
63. Positive clinical trial result on BSSL. http://www.ppl-therapeutics.com/news/news_2_content_15.asp 2001.
64. Van Cott K, Lubon H, Russell C, et al. Phenotypic and genotypic stability of multiple lines of transgenic pigs expressing recombinant human protein C. Transgenic Res., 1997 ;6(3): 203-212.
65. Van Cott K, Lubon H, Gwazdauskas F, et al. Recombinant human protein C expression in the milk of transgenic pigs and the effect on endogenous milk immunoglobulin and transferrin levels. Transgenic Res., 2001 ;10(1): 43-51.
66. Uusi M, Hyttinen J, Korhonen V, et al. Bovine as1-casein gene sequences direct high level expression of human granulocyte-macrophage colony-stimulating factor in the milk of transgenic mice. Transgenic Res., 1997 ;6(1): 75-84.
67. Hematech Scientific Publications. http://www.hematech.com/hematech/publications/default.asp 2004.
68. Cloned Cows Generate Human Antibodies. Nature Biotechnol., 2002; 10: 1038.
69. Therapeutic Human Polyclonals Products. http://www.polyclonals.com/index.html 2004.
70. Birse D, Lacroix D, Dyck M, et al. Biotherapeutics from Transgenic Porcine Sources: Bioprocessing Approaches and Challenges. Bio-Processing J., 2004; March/April: 37-44.
71. Ryoo Z, Kim M, Kim K, et al. Expression of recombinant human granulocyte macrophagecolony stimulating factor (hGM-CSF) in mouse urine. Transgenic Res., 2001 ;10(3): 193-200.
72. Utilizing the Bladder as a Bioreactor in Transgenic Animals. http://www.med.nyu.edu/OIL/Biotech/BSun.html 2004.
73. Kerr DE, Liang F, Bondioli KR, et al. The bladder as a bioreactor: urothelium production and secretion of growth hormone into urine. Nat Biotechnol. 1998 ;16(1): 75-79.
74. Advanced Bionutrition Crustacean Expression System. http://www.advancedbionutrition.-com/html/prod_platforms.html#crustacean 2004.
75. Chesapeake PERL Technology. http://www.c-perl.com/2004.
76. Advanced Cell Technology Scientific Publications. http://www.advancedcell.com/Scientific-papers.htm 2004.
77. Nextran Information. http://www.baxter.ca/htdocs/en/doctors/renal_therapies/nextran.html 2004.
78. AviGenics Technology Overview. http://www.avigenics.com/services.htm 2004.
79. Rapp JC, Harvey AJ, Speksnijder GL, et al. Biologically active human interferon alpha-2b produced in the egg white of transgenic hens. Transgenic Res., 2003 ;12(5): 569-575.
80. BioAgri Products. http://www.bioagricorp.com/strategic.aspx 2004.
81. Alper J. Biotechnology. Hatching the golden egg: a new way to make drugs. Science, 2003 ;300(5620): 729-730.
82. Chang K, Qian J, Jiang M, et al. Effective generation of transgenic pigs and mice by linker based sperm-mediated gene transfer. BMC Biotechnol., 2002 ;2(1): 5.
83. Coghlan A. Big breakfast -Crack open an egg and cure a disease. New Scientist Magazine, 1999; 11.
84. GenWay Biotech Products. http://www.genwaybio.com/DesktopPage.aspx?TabID=3329=en-US 2004.
85. Etches RJ, Verrinder Gibbins AM. Strategies for the production of transgenic chicken. Methods Mol. Biol., 1997; 62: 433-450.
86. Linda Foster Benedict. Transforming Chickens to Lay 'Golden' Eggs. Louisiana Agriculture Magazine OnLine 2003; 46(4).
87. TranXenoGen Technology. http://www.tranxenogen. com/NewFiles/background.html 2004.
88. Viragen Avian Technology. http://www.viragen.com/avian_intro.htm 2004.
89. Vivalis Transgenics Information. http://www.vivalis.com/2004.
90. Pain B, Chenevier P, Samarut J. Chicken embryonic stem cells and transgenic strategies. Cells Tissues Organs, 1999; 165(3/4): 212-219.
91. Menassa R, Kennette W, Nguyen V, et al. Subcellular targeting of human interleukin-10 in plants. J. Biotechnol., 2004; 108(2): 179-183.
92. Pacific NorthWest Laboratories Transgenic Plants Patents. http://availabletechnologies. pnl.gov/biomedical/trans.stm 2004.
93. Dai Z, Hooker BS, Anderson DB, et al. Expression of Acidothermus cellulolyticus endoglucanase E1 in transgenic tobacco: biochemical characteristics and physiological effects. Transgenic Res., 2000; 9(1): 43-54.
94. Hooker B, Dai Z, Gao J, et al., inventors; Transgenic Plant-derived Human Blood Coagulation Factors. 1999. PCT-World Intellectual Property Organization WO 99/58699.
95. Plants make blood coagulants. Chemical & Engineering News 1999; 44.
96. Hooker B, Dai Z, Kingsley M, et al., inventors; Method for Producing Human Growth Factors from Whole Plants or Plant Cell Culture. 1998. PCT-World Intellectual Property Organization WO98/21348.
97. Gao J, Hooker BS, Anderson DB. Expression of functional human coagulation factor XIII A-domain in plant cell suspensions and whole plants. Protein Expr. Purif., 2004; 37(1): 89-96.
98. Hooker B. Two Crops, One Plant. BioPharm., 1999; 29-30.
99. Warzecha H, Mason HS. Benefits and risks of antibody and vaccine production in transgenic plants. J. Plant Physiol., 2003; 160(7): 755-764.
100. Smith ML, Richter L, Arntzen CJ, et al. Structural characterization of plant-derived hepatitis B surface antigen employed in oral immunization studies. Vaccine, 2003; 21(25/26): 4011-4021.
101. Warzecha H, Mason HS, Lane C, et al. Oral immunogenicity of human papillomaviruslike particles expressed in potato. J. Virol., 2003; 77(16): 8702-8711.
102. Walmsley AM, Alvarez ML, Jin Y, et al. Expression of the B subunit of Escherichia coli heat-labile enterotoxin as a fusion protein in transgenic tomato. Plant Cell Rep., 2003; 21(10): 1020-1026.
103. Axis Genetics and Biomira sign research collaboration for the development of a cancer vaccine. http://www.biomira.com/news/detailNewsRelease/89/:November 9, 1998.
104. Ramirez N, Ayala M, Lorenzo D, et al. Expression of a single-chain Fv antibody fragment specific for the hepatitis B surface antigen in transgenic tobacco plants. Transgenic Res., 2002; 11(1): 61-64.
105. Lopez L, Muller R, Balmori E, et al. Molecular cloning and nucleotide sequence of the coat protein gene of a Cuban isolate of potato leafroll virus and its expression in Escherichia coli. Virus Genes, 1994; 9(1): 77-83.
106. Carrillo C, Wigdorovitz A, Trono K, et al. Induction of a virus-specific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants. Viral Immunol., 2001; 14(1): 49-57.
107. Gil F, Brun A, Wigdorovitz A, et al. Highyield expression of a viral peptide vaccine in transgenic plants. FEBS Lett., 2001; 488(1/2): 13-17.
108. Gomez N, Wigdorovitz A, Castanon S, et al. Oral immunogenicity of the plant derived spike protein from swine-transmissible gastroenteritis coronavirus. Arch. Virol., 2000; 145(8): 1725-1732.
109. Wigdorovitz A, Carrillo C, Dus Santos MJ, et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1 Virology, 1999; 255(2): 347-353.
110. Carrillo C, Wigdorovitz A, Oliveros JC, et al. Protective immune response to foot-andmouth disease virus with VP1 expressed in transgenic plants. J. Virol., 1998; 72(2): 1688-1690.
111. Chlorogen Technology. http://www.chlorogen. com/technology.htm 2004.
112. Daniell H, Khan MS, Allison L. Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci., 2002 ;7(2): 84-91.
113. Daniell H, Lee SB, Panchal T, et al. Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J. Mol. Biol. 2001 ;311(5): 1001-1009.
114. Rachel Melcer. Creve Coeur Startup Develops Human Plasma from Tobacc. St. Louis Post-Dispatch. June 20, 2003.
115. Kang TJ, Loc NH, Jang MO, et al. Expression of the B subunit of E. coli heat-labile enterotoxin in the chloroplasts of plants and its characterization. Transgenic Res., 2003 ;12(6): 683-691.
116. Cobento Biotech products. http://www.cobento.com/2004.
117. Bouquin T, Thomsen M, Nielsen L, et al. Human Anti-Rhesus D IgG1 Antibody Produced in Transgenic Plants. Transgenic Res., 2002 ;11(2): 115-122.
118. Tavladoraki P, Benvenuto E, Trinca S, et al. Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack. Nature, 1993 ;366(6454): 469-472.
119. Benvenuto E, Ordas RJ, Tavazza R, et al. 'Phytoantibodies': a general vector for the expression of immunoglobulin domains in transgenic plants. Plant Mol. Biol., 1991 ;17(4): 865-874.
120. Vine ND, Drake P, Hiatt A, et al. Assembly and plasma membrane targeting of recombinant immunoglobulin chains in plants with a murine immunoglobulin transmembrane sequence. Plant Mol. Biol., 2001 ;45(2): 159-167.
121. Ma JK, Hiatt A, Hein M, et al. Generation and assembly of secretory antibodies in plants. Science, 1995 ;268(5211): 716-719.
122. Ma JK, Lehner T, Stabila P, et al. Assembly of monoclonal antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants. Eur. J. Immunol., 1994 ;24(1): 131-138.
123. Hiatt A, Ma JK. Monoclonal antibody engineering in plants. FEBS Lett., 1992 ;307(1): 71-75.
124. Hiatt A, Cafferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature, 1989 ;342(6245): 76-78.
125. ERA Biotech Technology. http://www.eraplantech.com/ang/zera.html 2004.
126. Yang IC, Iommarini JP, Becker DK, et al. A promoter derived from taro bacilliform badnavirus drives strong expression in transgenic banana and tobacco plants. Plant Cell Rep., 2003 ;21(12): 1199-1206.
127. Farmacule Technology. http://www.farmacule.com/technology.htm#T22004.
128. Fraunhofer Center for Molecular Biology Technology. http://www.fraunhofer-cmb.org/index.cfm?act=technology 2004.
129. Stoger E, Schillberg S, Twyman RM, et al. Antibody production in transgenic plants. Methods Mol. Biol., 2004; 248: 301-318.
130. Fischer R, Schumann D, Zimmermann S, et al. Expression and characterization of bispecific single-chain Fv fragments produced in transgenic plants. Eur. J. Biochem., 1999 ;262(3): 810-816.
131. de Zoeten GA, Penswick JR, Horisberger MA, et al. The expression, localization, and effect of a human interferon in plants. Virology, 1989 ;172(1): 213-222.
132. Peeters K, De Wilde C, De Jaeger G, et al. Production of antibodies and antibody fragments in plants. Vaccine, 2001; 19(17-19): 2756-2761.
133. Peeters K, De Wilde C, Depicker A. Highly efficient targeting and accumulation of a F(ab) fragment within the secretory pathway and apoplast of Arabidopsis thaliana. Eur. J. Biochem., 2001 ;268(15): 4251-4260.
134. De Jaeger G, De Wilde C, Eeckhout D, et al. The plantibody approach: expression of antibody genes in plants to modulate plant metabolism or to obtain pathogen resistance. Plant Mol. Biol., 2000 ;43(4): 419-428.
135. De Jaeger G, Buys E, Eeckhout D, et al. High level accumulation of single-chain variable fragments in the cytosol of transgenic Petunia hybrida. Eur. J. Biochem., 1999; 259(1/2): 426-434.
136. Bruyns AM, De Jaeger G, De Neve M, et al. Bacterial and plant-produced scFv proteins have similar antigen-binding properties. FEBS Lett., 1996 ;386(1): 5-10.
137. De Neve M, De Loose M, Jacobs A, et al. Assembly of an antibody and its derived antibody fragment in Nicotiana and Arabidopsis. Transgenic Res., 1993 ;2(4): 227-237.
138. Edelbaum O, Stein D, Holland N, et al. Expression of active human interferon-beta in transgenic plants. J. Interferon Res., 1992 ;12(6): 449-453.
139. Rosenberg N, Reichman M, Gera A, et al. Antiviral activity of natural and recombinant human leukocyte interferons in tobacco protoplasts. Virology, 1985 ;140(1): 173-178.
140. Ohya K, Itchoda N, Ohashi K, et al. Expression of biologically active human tumor necrosis factor-alpha in transgenic potato plant. J. Interferon Cytokine Res., 2002 ;22(3): 371-378.
141. Ohya K, Matsumura T, Ohashi K, et al. Expression of two subtypes of human IFN-alpha in transgenic potato plants. J. Interferon Cytokine Res., 2001 ;21(8): 595-602.
142. Icon Genetics Products. http://www.icongenetics.com/html/tech3_6.htm 2004.
143. Marillonnet S, Giritch A, Gils M, et al. In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc. Natl. Acad. Sci. USA, 2004 ;101(18): 6852-6857.
144. Gleba Y, Marillonnet S, Klimyuk V. Engineering viral expression vectors for plants: the 'full virus' and the 'deconstructed virus' strategies. Curr. Opin. Plant Biol., 2004 ;7(2): 182-188.
145. Borisjuk NV, Borisjuk LG, Logendra S, et al. Production of recombinant proteins in plant root exudates. Nature Biotechnol., 1999 ;17(5): 466-469.
146. Biemelt S, Sonnewald U, Galmbacher P, et al. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J. Virol., 2003 ;77(17): 9211-9220.
147. Scheller J, Guhrs KH, Grosse F, et al. Production of spider silk proteins in tobacco and potato. Nature Biotechnol., 2001 ;19(6): 573-577.
148. Fiedler U, Conrad U. High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds. Biotechnology (NY), 1995 ;13(10): 1090-1093.
149. Artsaenko O, Peisker M, Zur NU, et al. Expression of a single-chain Fv antibody against abscisic acid creates a wilty phenotype in transgenic tobacco. Plant J., 1995 ;8(5): 745-750.
150. Conrad U, Fiedler U. Expression of engineered antibodies in plant cells. Plant Mol. Biol., 1994 ;26(4): 1023-1030.
151. Scheller J, Henggeler D, Viviani A, et al. Purification of spider silk-elastin from transgenic plants and application for human chondrocyte proliferation. Transgenic Res., 2004 ;13(1): 51-57.
152. Byun K, Hong J, Lee C, et al., inventors; KIST SK, assignee. Human interleukin-6 producing tobacco. 1996.
153. Matsumoto S, Ikura K, Ueda M, et al. Characterization of a human glycoprotein (erythropoietin) produced in cultured tobacco cells. Plant Mol. Biol., 1995 ;27(6): 1163-1172.
154. Matsumoto S, Ishii A, Ikura K, et al. Expression of human erythropoietin in cultured tobacco cells. Biosci. Biotechnol. Biochem., 1993 ;57(8): 1249-1252.
155. D'Aoust M, Busse U, et al. In: Fischer R, Schillberg S (Eds), Molecular Farming: Plant-made Pharmaceuticals and Technical Proteins. Wiley-VCH; 2004.
156. Medicago Technology. http://www2.medicago. com/en/tech_platform/proficia/2004.
157. Busse ULVTSeVLP. In: L. Erickson W-JYJB, Rymerson R (Eds), Molecular Farming of Plants and Animals for Human and Veterinary Medicine. Kluwer Academic Publishers; 2002.
158. D'Aoust M, Busse U, et al. In: Christou P, Klee H (Eds), Handbook of Plant Biotechnology. Wiley & Sons; 2004.
159. Meristem Products. http://www.meristem-therapeutics.com/2004.
160. Perret S, Merle C, Bernocco S, et al. Unhydroxylated triple helical collagen I produced in transgenic plants provides new clues on the role of hydroxyproline in collagen folding and fibril formation. J. Biol. Chem., 2001 ;276(47): 43693-43698.
161. Samyn-Petit B, Wajda Dubos JP, Chirat F, et al. Comparative analysis of the site-specific N-glycosylation of human lactoferrin produced in maize and tobacco plants. Eur. J. Biochem., 2003 ;270(15): 3235-3242.
162. Mokrzycki-Issartel N, Bouchon B, Farrer S, et al. A transient tobacco expression system coupled to MALDI-TOF-MS allows validation of the impact of differential targeting on structure and activity of a recombinant therapeutic glycoprotein produced in plants. FEBS Lett., 2003; 552(2/3): 170-176.
163. Merle C, Perret S, Lacour T, et al. Hydroxylated human homotrimeric collagen I in Agrobacterium tumefaciens-mediated transient expression and in transgenic tobacco plant. FEBS Lett., 2002; 515(1-3): 114-118.
164. Samyn-Petit B, Gruber V, Flahaut C, et al. N-glycosylation potential of maize: the human lactoferrin used as a model. Glycoconj J., 2001 ;18(7): 519-527.
165. Theisen M. Production of recombinant blood factors in transgenic plants. Adv. Exp. Med. Biol., 1999; 464: 211-220.
166. Gruber V, Berna P, Arnaud T, et al. Largescale production of a therapeutic protein in transgenic tobacco plants: effect of subcellular targeting on quality of a recombinant dog gastric lipase. Molecular Breeding, 2001 ;7(4): 329-340.
167. Ruggiero F, Exposito JY, Bournat P, et al. Triple helix assembly and processing of human collagen produced in transgenic tobacco plants. FEBS Lett., 2000 ;469(1): 132-136.
168. Dieryck W, Pagnier J, Poyart C, et al. Human haemoglobin from transgenic tobacco. Nature, 1997 ;386(6620): 29-30.
169. Sijmons PC, Dekker BM, Schrammeijer B, et al. Production of correctly processed human serum albumin in transgenic plants. Biotechnology (NY), 1990 ;8(3): 217-221.
170. Schlittler MR, Taylor DW, Russell DA, et al. Production of human somatotropin from corn seed. Am. Chem. Soc., 221st BIOT-019, 2001.
171. Baez J, Russell D, Craig J. Corn Seed Production of Therapeutic Proteins Moves Forward. BioPharm., 2000; 3.
172. Baez J, Russell D. Characterization of human monoclonal antibodies produced in plan. 219th ACS National Meeting, San Francisco, CA, March 26-30, 2000, BIOT-018, 2000.
173. Staub JM, Garcia B, Graves J, et al. Highyield production of a human therapeutic protein in tobacco chloroplasts. Nature Biotechnol., 2000 ;18(3): 333-338.
174. Russell DA. Feasibility of antibody production in plants for human therapeutic use. Curr. Top. Microbiol. Immunol., 1999; 240: 119-138.
175. Zeitlin L, Olmsted SS, Moench TR, et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nature Biotechnol., 1998 ;16(13): 1361-1364.
176. Francisco JA, Gawlak SL, Miller M, et al. Expression and characterization of bryodin 1 and a bryodin 1-based single-chain immunotoxin from tobacco cell culture. Bioconjug. Chem., 1997 ;8(5): 708-713.
177. Olsen D, Yang C, Bodo M, et al. Recombinant collagen and gelatin for drug delivery. Adv. Drug Deliv. Rev., 2003 ;55(12): 1547-1567.
178. Webster DE, Thomas MC, Strugnell RA, et al. Appetising solutions: an edible vaccine for measles. Med. J. Aust., 2002 ;176(9): 434-437.
179. Webster DE, Cooney ML, Huang Z, et al. Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J. Virol., 2002 ;76(15): 7910-7912.
180. Huang Z, Dry I, Webster D, et al. Plant-derived measles virus hemagglutinin protein induces neutralizing antibodies in mice. Vaccine, 2001; 19(15/16): 2163-2171.
181. Tawaiwa F, Katsumata K, Anzai H. Production of human lactoferrin in transgenic plants. 2nd International Molecular Farming Conference; London, Ontario, Canada, 1999.
182. Takase K, Hagiwara K. Expression of human alpha-lactalbumin in transgenic tobacco. J. Biochem. (Tokyo), 1998 ;123(3): 440-444.
183. Higo K, Saito Y, Higo H. Expression of a chemically synthesized gene for human epidermal growth factor under the control of cauliflower mosaic virus 35S promoter in transgenic tobacco. Biosci. Biotechnol. Biochem., 1993 ;57(9): 1477-1481.
184. NexGen Molecular Pharming Program. http://www.campnexgen.com/english/mf/mf.htm 2004.
185. Allina S, Heng Lui Y, Him S, et al. Production of a Canine oral papillomavirus vaccine in Tobacco. 2nd International Molecular Farming Conference; London, Ontario, Canada, 1999.
186. Phylogix Information. http://www.phylogix.com/about_us.htm 2004.
187. Moore JG, Fuchs CA, Hata YS, et al. A new lectin in red kidney beans called PvFRIL stimulates proliferation of NIH 3T3 cells expressing the Flt3 receptor. Biochim. Biophys. Acta, 2000 ;1475(3): 216-224.
188. Planet Biotechnology Publications. http://www.planetbiotechnology.com/publications. html 2004.
189. Larrick JW, Thomas DW. Producing proteins in transgenic plants and animals. Curr. Opin. Biotechnol., 2001; 12: 411-418.
190. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci., 2001 ;6(5): 219-226.
191. Larrick JW, Yu L, Naftzger C, et al. Production of secretory IgA antibodies in plants. Biomol. Eng., 2001 ;18(3): 87-94.
192. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci., 2001 ;6(5): 219-226.
193. Larrick JW, Yu L, Chen J, et al. Production of antibodies in transgenic plants. Res. Immunol., 1998 ;149(6): 603-608.
194. Ma JK, Hikmat BY, Wycoff K, et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nature Med., 1998 ;4(5): 601-606.
195. Plantigen technology. http://www.lhsc.on.ca/plantigen/science_tech.html 2004.
196. Ma S, Huang Y, Yin Z, et al. Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Proc. Natl. Acad. Sci. USA, 2004 ;101(15): 5680-5685.
197. Menassa R, Kennette W, Nguyen V, et al. Subcellular targeting of human interleukin-10 in plants. J. Biotechnol., 2004 ;108(2): 179-183.
198. Ma S, Jevnikar AM. Autoantigens produced in plants for oral tolerance therapy of autoimmune diseases. Adv. Exp. Med. Biol., 1999; 464: 179-194.
199. Ma SW, Zhao DL, Yin ZQ, et al. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Med., 1997 ;3(7): 793-796.
200. Kong Q, Richter L, Yang YF, et al. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA, 2001 ;98(20): 11539-11544.
201. Ma JK, Drake PM, Christou P. The production of recombinant pharmaceutical proteins in plants. Nature Rev. Genet., 2003 ;4(10): 794-805.
202. Avesani L, Falorni A, Battista G, et al. Improved in planta expression of the human islet autoantigen glutamic acid decarboxylase (GAD65). Transgenic Res., 2003 ;12(2): 203-212.
203. Tuboly T, Yu W, Bailey A, et al. Immunogenicity of porcine transmissible gastroenteritis virus spike protein expressed in plants. Vaccine, 2000 ;18(19): 2023-2028.
204. Du S, Yu W, DeLange C, et al. Expression of Porcine Epidermal Growth Factor in Plants. International Molecular Farming Conference; London, Ontario, Canada, 1999.
205. Desai UA, Sur G, Daunert S, et al. Expression and affinity purification of recombinant proteins from plants. Protein Expr. Purif., 2002 ;25(1): 195-202.
206. Li Q, Lawrence CB, Xing HY, et al. Enhanced disease resistance conferred by expression of an antimicrobial magainin analog in transgenic tobacco. Planta, 2001 ;212(4): 635-639.
207. Rigano MM, Alvarez ML, Pinkhasov J, et al. Production of a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep., 2004 ;22(7): 502-508.
208. Rigano MM, Sala F, Arntzen CJ, et al. Targeting of plant-derived vaccine antigens to immunoresponsive mucosal sites. Vaccine, 2003; 21(7/8): 809-811.
209. Sala F, Manuela RM, Barbante A, et al. Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives. Vaccine, 2003; 21(7/8): 803-808.
210. Franconi R, Di Bonito P, Dibello F, et al. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res., 2002 ;62(13): 3654-3658.
211. Franconi R, Roggero P, Pirazzi P, et al. Functional expression in bacteria and plants of an scFv antibody fragment against topo-viruses. Immunotechnology, 1999; 4(3/4): 189-201.
212. Bakker H, Bardor M, Molthoff JW, et al. Galactose-extended glycans of antibodies produced by transgenic plants. Proc. Natl. Acad. Sci. USA, 2001 ;98(5): 2899-2904.
213. Schouten A, Roosien J, de Boer JM, et al. Improving scFv antibody expression levels in the plant cytosol. FEBS Lett., 1997 ;415(2): 235-241.
214. Schouten A, Roosien J, van Engelen FA, et al. The C-terminal KDEL sequence increases the expression level of a single-chain antibody designed to be targeted to both the cytosol and the secretory pathway in transgenic tobacco. Plant Mol. Biol., 1996 ;30(4): 781-793.
215. van Engelen FA, Schouten A, Molthoff JW, et al. Coordinate expression of antibody subunit genes yields high levels of functional antibodies in roots of transgenic tobacco. Plant Mol. Biol., 1994 ;26(6): 1701-1710.
216. Elbers I, Stoopen G, Bakker H, et al. Influence of growth conditions and developmental stage on N-glycan heterogeneity of transgenic immunoglobulin G and endogenous proteins in tobacco leaves. Plant Physiol., 2001; 126: 1314-1322.
217. Zhang G, Leung C, Murdin L, et al. In planta expression of HIV-1 p24 protein using an RNA plant virus-based expression vector. Mol. Biotechnol., 2000 ;14(2): 99-107.
218. Agrenvec Information. http://agrenvec.com/eng/2004.
219. Sanchez F, Wang X, Jenner CE, et al. Strains of Turnip mosaic potyvirus as defined by the molecular analysis of the coat protein gene of the virus. Virus Res., 2003 ;94(1): 33-43.
220. Jenner CE, Sanchez F, Nettleship SB, et al. The cylindrical inclusion gene of Turnip mosaic virus encodes a pathogenic determinant to the Brassica resistance gene TuRB01. Mol. Plant Microbe Interact., 2000 ;13(10): 1102-1108.
221. Roggero P, Ciuffo M, Benvenuto E, et al. The expression of a single-chain Fv antibody fragment in different plant hosts and tissues by using Potato virus X as a vector. Protein Expr. Purif., 2001 ;22(1): 70-74.
222. Yusibov V, Hooper DC, Spitsin SV, et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine, 2002; 20(25/26): 3155-3164.
223. Koprowski H, Yusibov V. The green revolution: plants as heterologous expression vectors. Vaccine, 2001; 19(17-19): 2735-2741.
224. Belanger H, Fleysh N, Cox S, et al. Human respiratory syncytial virus vaccine antigen produced in plants. FASEB J., 2000 ;14(14): 2323-2328.
225. Yusibov V, Shivprasad S, Turpen TH, et al. Plant viral vectors based on tobamoviruses. Curr. Top. Microbiol. Immunol., 1999; 240: 81-94.
226. Kapusta J, Modelska A, Figlerowicz M, et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J., 1999 ;13(13): 1796-1799.
227. Yusibov V, Shivprasad S, Turpen TH, et al. Plant viral vectors based on tobamoviruses. Curr. Top. Microbiol. Immunol., 1999; 240: 81-94.
228. Verch T, Yusibov V, Koprowski H. Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector. J. Immunol. Methods, 1998; 220(1/2): 69-75.
229. Modelska A, Dietzschold B, Sleysh N, et al. Immunization against rabies with plant-derived antigen. Proc. Natl. Acad. Sci. USA, 1998 ;95(5): 2481-2485.
230. Fraunhofer Vaccine Development Technology. http://www.fraunhofer-cmb.org/index.cfm?act=tech_VaccineDevelopment 2004.
231. Marillonnet S, Giritch A, Gils M, et al. In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc. Natl. Acad. Sci. USA, 2004 ;101(18): 6852-6857.
232. Crabtree P. Rincon Pharmaceutical. San Diego, Union-Tribune, May 20, 2005.
233. Fischer R, Schillberg S. Molecular Farming -Plant made pharamaceuticals and technical proteins. Weinheim, Wiley-VCH, 2004.
234. Gelderman M, Oliver K, Yazdani A, et al. Preclinical Studies with Plant-Produced alpha-Galactosidase A in Fabry Mice Show Potential for Replacement Therapy. NA. Preclinica, 2004 ;2(1): 67-74.
235. Kumagai MH, Donson J, Della-Cioppa G, et al. Rapid, high-level expression of glycosylated rice alpha-amylase in transfected plants by an RNA viral vector. Gene, 2000 ;245(1): 169-174.
236. McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl. Acad. Sci. USA, 1999 ;96(2): 703-708.
237. Turpen TH, Reinl SJ, Charoenvit Y, et al. Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology (NY), 1995 ;13(1): 53-57.
238. Large Scale Biology Corporation Announces Biomanufacturing and Commercial Distribution Agreement with Sigma-Aldrich Corporation. March 6, 04 Wall Street Reporter 2004.
239. Joint NIH And Large Scale Biology Corporation (LSBC) Studies With Plant-Produced Alpha-Galactosidase Show Its Potential For Enzyme Replacement Therapy In Fabry Disease. http://www.biospace.com/news_story.cfm? StoryID=14899320&full=1 2004.
240. Tacket CO, Mason HS, Losonsky G, et al. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis., 2000 ;182(1): 302-305.
241. Dai Z, Hooker BS, Anderson DB, et al. Expression of Acidothermus cellulolyticus endoglucanase E1 in transgenic tobacco: biochemical characteristics and physiological effects. Transgenic Res., 2000 ;9(1): 43-54.
242. Farran I, Sanchez-Serrano JJ, Medina JF, et al. Targeted expression of human serum albumin to potato tubers. Transgenic Res., 2002 ;11(4): 337-346.
243. Chong DK, Langridge WH. Expression of full-length bioactive antimicrobial human lactoferrin in potato plants. Transgenic Res., 2000 ;9(1): 71-78.
244. Arakawa T, Yu J, Chong DK, et al. A plantbased cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nature Biotechnol., 1998 ;16(10): 934-938.
245. Arakawa T, Langridge WH. Plants are not just passive creatures! Nature Med., 1998; 4(5): 550-551.
246. Arakawa T, Chong DK, Langridge WH. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nature Biotechnol., 1998 ;16(3): 292-297.
247. Arakawa T, Chong DK, Merritt JL, et al. Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res., 1997 ;6(6): 403-413.
248. During K, Hippe S, Kreuzaler F, et al. Synthesis and self-assembly of a functional monoclonal antibody in transgenic Nicotiana tabacum. Plant Mol. Biol., 1990 ;15(2): 281-293.
249. Klaus During. Engineered storage organs as bioreactors for protein production. 2nd International Molecular Farming Conference; London, Ontario, Canada, 1999.
250. Collins S. Potato the medical factory of tomorro. New Zealand Herald. April 23, 2003.
251. Novoplant Technology. http://www.novoplant.de/2004.
252. Planton technology. http://www.planton.de/en/index.html 2004.
253. Malaysia Rubber Institute Biotechnology and Strategic Research Unit. http://www.lgm.gov.my/r&d/bsru/transgenic.html 2004.
254. Arokiaraj P, Rueker F, Carter D, et al. Expression of Human Serum Albumin in the laticifers of Transgenic Hevea brasiliensis. International Molecular Farming Conference; London, Ontario, Canada, 1999.
255. Yeang, H. Engineering Crop Plants for Industrial End Uses. London, UK: Portland Press; 1998: 55-64.
256. Rod Santa Ana III. Medical proteins from sugarcane. Farm Press online, USA 2003.
257. Michael Smith. Norwalk virus vaccine grown in tomatoe. United Press International. February 16, 2003.
258. Sandhu JS, Krasnyanski SF, Domier LL, et al. Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response. Transgenic Res., 2000 ;9(2): 127-135.
259. Jani D, Singh NK, Bhattacharya S, et al. Studies on the immunogenic potential of plant-expressed cholera toxin B subunit. Plant Cell Rep., 2004 ;22(7): 471-477.
260. Jani D, Meena LS, Rizwan-ul-Haq QM, et al. Expression of cholera toxin B subunit in transgenic tomato plants. Transgenic Res., 2002 ;11(5): 447-454.
261. Arazi T, Lee HP, Huang PL, et al. Production of antiviral and antitumor proteins MAP30 and GAP31 in cucurbits using the plant virus vector ZYMV-AGII. Biochem. Biophys. Res. Commun., 2002 ;292(2): 441-448.
262. Cropdesign Technology. http://www.cropdesign.com 2004.
263. Dow Plant Technology. http://www.dow.com/plantbio 2004.
264. Frigerio L, Vine ND, Pedrazzini E, et al. Assembly, secretion, and vacuolar delivery of a hybrid immunoglobulin in plants. Plant Physiol., 2000 ;123(4): 1483-1494.
265. Company of the Month: Epicyte. http://www.biotechjournal.com/Journal/Jun2001/juneartA2001.pdf 2001; San Diego Biotech Journal.
266. Stoger E, Vaquero C, Torres E, et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol. Biol., 2000 ;42(4): 583-590.
267. Perrin Y, Vasquero C, Gerrard I, et al. Transgenic pea seeds as bioreactors for the production of a single-chain Fv fragment antibodies used in cancer diagnosis and therapy. Molecular Breeding, 2000; 6: 345-352.
268. Vandekerckhove J, Van Damme J, Van Lijsebetten M, et al. Enkephalins produced in transgenic plants using modified 2S seed storage proteins. Bio/Technology, 1989; 7: 929-932.
269. De Jaeger G, Scheffer S, Jacobs A, et al. Evaluation of Phaseolus vulgaris arcelin-5I gene for single-chain antibody production in transgenic plants. European Society Plant Physiology Annual Meeting, Helsinki, Finland, 2001.
270. Mäkinen K. Production of recombinant gelatin in barley. http://www.honeybee.helsinki.fi/mmsbl/Biokemlab/makinen/research.html 2004.
271. Chikwamba R, Cunnick J, Hathaway D, et al. A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res., 2002 ;11(5): 479-493.
272. Yang SH, Moran DL, Jia HW, et al. Expression of a synthetic porcine alpha-lactalbumin gene in the kernels of transgenic maize. Transgenic Res., 2002 ;11(1): 11-20.
273. Eudes F, Gilbert S, Acharya S, et al. Expression of a Bovine Virus Protein in Barley: a Potential Edible Vaccine. 2nd International Molecular Farming Conference; London, Ontario, Canada, 1999.
274. Maltagene Technology. http://www.maltagen. de/index-english.htm 2004.
275. Mokrzycki-Issartel N, Bouchon B, Farrer S, et al. A transient tobacco expression system coupled to MALDI-TOF-MS allows validation of the impact of differential targeting on structure and activity of a recombinant therapeutic glycoprotein produced in plants. FEBS Lett., 2003; 552(2/3): 170-176.
276. Schlittler MR, Taylor DW, Russell DA, et al. Production of human somatotropin from corn seed. Am. Chem. Soc., 221st BIOT-019 2001.
277. Novoplant Technology. http://www.novoplant. de/2004.
278. Orf Genetics Technology. http://www.orfgenetics.com/orf/wgorf.nsf/key2/Technology 2004.
279. Bailey MR, Woodard SL, Callaway E, et al. Improved recovery of active recombinant laccase from maize seed. Appl. Microbiol. Biotechnol., 2004 ;63(4): 390-397.
280. Woodard SL, Mayor JM, Bailey MR, et al. Maize (Zea mays)-derived bovine trypsin: characterization of the first large-scale, commercial protein product from transgenic plants. Biotechnol. Appl. Biochem., 2003; 38(Pt 2): 123-130.
281. Lamphear BJ, Streatfield SJ, Jilka JM, et al. Delivery of subunit vaccines in maize seed. J. Control. Release, 2002; 85(1-3): 169-180.
282. Streatfield SJ, Jilka JM, Hood EE, et al. Plant-based vaccines: unique advantages. Vaccine, 2001; 19(17-19): 2742-2748.
283. Azzoni AR, Kusnadi AR, Miranda EA, et al. Recombinant aprotinin produced in transgenic corn seed: extraction and purification studies. Biotechnol. Bioeng., 2002 ;80(3): 268-276.
284. Evangelista RL, Kusnadi AR, Howard JA, et al. Process and economic evaluation of the extraction and purification of recombinant beta-glucuronidase from transgenic corn. Biotechnol. Prog., 1998 ;14(4): 607-614.
285. Kusnadi AR, Hood EE, Witcher DR, et al. Production and purification of two recombinant proteins from transgenic corn. Biotechnol. Prog., 1998 ;14(1): 149-155.
286. Hood E. From green plants to industrial enzymes. Enzyme Microbial Technol., 2002 ;30(3): 279-283.
287. Lamphear BJ, Jilka JM, Kesl L, et al. A cornbased delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine. Vaccine, 2004 ;22(19): 2420-2424.
288. Horn ME, Pappu KM, Bailey MR, et al. Advantageous features of plant-based systems for the development of HIV vaccines. J Drug Target., 2003; 11(8-10): 539-545.
289. Streatfield SJ, Lane JR, Brooks CA, et al. Corn as a production system for human and animal vaccines. Vaccine, 2003; 21(7/8): 812-815.
290. Kusnadi AR, Evangelista RL, Hood EE, et al. Processing of transgenic corn seed and its effect on the recovery of recombinant betaglucuronidase. Biotechnol. Bioeng., 1998 ;60(1): 44-52.
291. Hood E, Witcher DR, Maddock S, et al. Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction, and purification. Mol. Breed., 1997; 3: 291-306.
292. Nicholson L, Christou P, Ma J, et al. Expression of recombinant SIgA in cereals. 2nd International Molecular Farming Conference; London, Ontario, Canada, 1999.
293. Stoger E, Vaquero C, Torres E, et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol. Biol., 2000 ;42(4): 583-590.
294. Moloney MM, Holbrook LA. Subcellular targeting and purification of recombinant proteins in plant production systems. Biotechnol. Genet. Eng. Rev., 1997; 14: 321-336.
295. van Rooijen GJ, Moloney MM. Plant seed oil-bodies as carriers for foreign proteins. Biotechnology (NY), 1995 ;13(1): 72-77.
296. Parmenter DL, Boothe JG, van Rooijen GJ, et al. Production of biologically active hirudin in plant seeds using oleosin partitioning. Plant Mol. Biol., 1995 ;29(6): 1167-1180.
297. Hogge L, Boothe J, Maloney M, et al. Structure Confirmation of Recombinant Hirudin Using MALDI with C-Terminal Sequencing. 2nd International Molecular Farming Conference; London, Ontario, Canada, 1999.
298. SunGene Technology. http://www.sungene.de/2004.
299. Syngenta BioPharma. http://www.syngenta.com/en/biopharma/2004.
300. Leite A, Kemper E, Bocaccorsi E, et al. Correctly Processed Human Growth Hormone is Expressed in Seeds of Transgenic Tobacco Plants. 2nd International Molecular Farming Conference; London, Ontario, Canada, 1999.
301. Tackaberry ES, Prior F, Bell M, et al. Increased yield of heterologous viral glycoprotein in the seeds of homozygous transgenic tobacco plants cultivated underground. Genome, 2003 ;46(3): 521-526.
302. Sardana RK, Alli Z, Dudani A, et al. Biological activity of human granulocyte-macrophage colony stimulating factor is maintained in a fusion with seed glutelin peptide. Transgenic Res., 2002 ;11(5): 521-531.
303. Wright KE, Prior F, Sardana R, et al. Sorting of glycoprotein B from human cytomegalovirus to protein storage vesicles in seeds of transgenic tobacco. Transgenic Res., 2001 ;10(2): 177-181.
304. Tackaberry ES, Dudani AK, Prior F, et al. Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacco. Vaccine, 1999; 17(23/24): 3020-3029.
305. Panahi M, Cheng X, Callagham M, et al. Expression of human insulin-like growth factor (IGF-I) in plants. 2nd International Molecular Farming Conference; London, Ontario, Canada, 1999.
306. Panahi M, Alli Z, Cheng X, et al. Recombinant protein expression plasmids optimized for industrial E. coli fermentation and plant systems produce biologically active human insulin-like growth factor-1 in transgenic rice and tobacco plants. Transgenic Res., 2004 ;13(3): 245-259.
307. Dalton R. California edges towards farming drug-producing rice. Nature, 2004 ;428(6983): 591.
308. Suzuki YA, Kelleher SL, Yalda D, et al. Expression, characterization, and biologic activity of recombinant human lactoferrin in rice. J. Pediatr. Gastroenterol. Nutr., 2003 ;36(2): 190-199.
309. Humphrey BD, Huang N, Klasing KC. Rice expressing lactoferrin and lysozyme has antibiotic-like properties when fed to chicks. J. Nutr., 2002 ;132(6): 1214-1218.
310. Torres E, Vaquero C, Nicholson L, et al. Rice cell culture as an alternative production system for functional diagnostic and therapeutic antibodies. Transgenic Res., 1999 ;8(6): 441-449.
311. Huang J, Sutliff TD, Wu L, et al. Expression and purification of functional human alpha-1-Antitrypsin from cultured plant cells. Biotechnol. Prog., 2001 ;17(1): 126-133.
312. Nandi S, Suzukib Y, Huang J, et al. Expression of human lactoferrin in transgenic rice grains for the application in infant formula. Plant Sci. 163(4): 713-722.
313. Huang J, Nandi S, Wu L, et al. Expression of natural antimicrobial human lysozyme in rice grains. Mol. Breeding, 2004; 10(1/2): 83-94.
314. Huang N. High-level Protein Expression System Uses Self-Pollinating Crops as Hosts. BioProcess Int., 2004; 54-59.
315. WSU Dieter Von Wettstein Research Interest. http://molecular.biosciences.wsu.edu/faculty/vonwettstein.html 2004.
316. Horvath H, Huang J, Wong O, et al. The production of recombinant proteins in transgenic barley grains. Proc. Natl. Acad. Sci. USA, 2000 ;97(4): 1914-1919.
317. Greenovation Technology. http://www.greenovation.com/Projects_Production. htm 2004.
318. Gasdaska J, Spencer D, Dickey L. Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna. BioProcessing J., 2003; 49-53.
319. Phycotransgenic Technology. http://www.phycotransgenics.com/2004.
320. Franklin SE, Mayfield SP. Prospects for molecular farming in the green alga Chlamydomonas. Curr Opin. Plant Biol., 2004 ;7(2): 159-165.
321. Mayfield SP, Franklin SE, Lerner RA. Expression and assembly of a fully active antibody in algae. Proc. Natl. Acad. Sci. USA, 2003 ;100(2): 438-442.
322. Borisjuk NV, Borisjuk LG, Logendra S, et al. Production of recombinant proteins in plant root exudates. Nature Biotechnol., 1999 ;17(5): 466-469.
323. Gleba D, Borisjuk NV, Borisjuk LG, et al. Use of plant roots for phytoremediation and molecular farming. Proc. Natl. Acad. Sci. USA, 1999 ;96(11): 5973-5977.
324. Gaume A, Komarnytsky S, Borisjuk N, et al. Rhizosecretion of recombinant proteins from plant hairy roots. Plant Cell Rep., 2003 ;21(12): 1188-1193.
325. Medina-Bolivar F, Cramer C. Production of recombinant proteins by hairy roots cultured in plastic sleeve bioreactors. Methods Mol. Biol., 2004; 267: 351-364.
326. Medina-Bolivar F, Wright R, Funk V, et al. A non-toxic lectin for antigen delivery of plant-based mucosal vaccines. Vaccine, 2003; 21(9/10): 997-1005.
327. Cramer CL, Boothe JG, Oishi KK. Transgenic plants for therapeutic proteins: linking upstream and downstream strategies. Curr. Top. Microbiol. Immunol., 1999; 240: 95-118.
328. Cramer CL, Weissenborn DL, Oishi KK, et al. Bioproduction of human enzymes in transgenic tobacco. Ann. N.Y. Acad. Sci., 1996; 792: 62-71.
329. Koivu K. Contained Plant Bioreactor. 4th International Conference, Production & Economics of Biopharmaceuticals. San Diego, California, 2001.
330. Unicrop Publications. http://www.unicrop.fi/index.jsp?p=74, 79, 88 2004.
331. Geert De Jaeger Research Team Plant Cell Culture Program. http://www.vib.be/Research/EN/Research+Departments/Department+of+Plant+Systems+Biology/Geert+De+Jaeger/2004.
332. Yano A, Maeda F, Takekoshi M. Transgenic tobacco cells producing the human monoclonal antibody to hepatitis B virus surface antigen. J. Med. Virol., 2004 ;73(2): 208-215.
333. Information update on Phytoprotein Biotech Pte Ltd. http://www.agenix.com/news/biotechnews11apr1.htm 2001.
334. Protalix Technology. http://www.protalix.-com/html/technology_technology.htm 2004.
335. ROOTec Technology. http://www.pharmaceutical-map.com/non-member/storefront_view.php?id=262004.
336. Tsoi BM, Doran PM. Effect of medium properties and additives on antibody stability and accumulation in suspended plant cell cultures. Biotechnol. Appl. Biochem., 2002; 35(Pt 3): 171-180.
337. Sharp JM, Doran PM. Characterization of monoclonal antibody fragments produced by plant cells. Biotechnol. Bioeng., 2001 ;73(5): 338-346.
338. Doran PM. Foreign protein production in plant tissue cultures. Curr. Opin. Biotechnol., 2000; 11: 199-204.
339. Mison D, Curling J. The industrial production costs of recombinant therapeutic proteins expressed in transgenic corn. Bio-Pharm, 2000; 48-54.
340. Young M. Production of biopharmaceutical proteins in the milk of transgenic animals. BioPharm, 1997 ;10(6): 34-38.
341. Price B. The Capacity and Capability 'Crunch': Myth or Reality. Plant-Made Pharmaceuticals conference, Quebec, Canada, 2003.
342. Palmer C, Lubon H, McManaman J. Transgenic mice expressing recombinant human protein C exhibit defects in lactation and impaired mammary gland development. Transgenic Res., 2003 ;12(3): 283-292.
343. Cabanes-Macheteau M, Fitchette-Laine AC, Loutelier-Bourhis C, et al. N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology, 1999 ;9(4): 365-372.
344. Gala FA, Morrison SL. V region carbohydrate and antibody expression. J. Immunol., 2004 ;172(9): 5489-5494.
345. Rifai A, Fadden K, Morrison SL, et al. The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J. Exp. Med., 2000 ;191(12): 2171-2182.
346. Chargelegue D, Vine N, van Dolleweerd C, et al. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res., 2000 ;9(3): 187-194.
347. United States Department of Agriculture. Field testing of plants engineered to produce pharmaceutical and industrial compound. 2003, pp. 11337-11340. United States Federal Register 68.
348. FDA-CBER. Points to Consider in the Manufacture and Testing of Therapeutic Proteins for Human Use Derived from Transgenic Animals. http://mbcr.bcm.tmc.edu/BEP/ERMB/ptc_tga.html 1995.
349. Bair J. Food Value Chain Perspective. Corn-Produced Pharmaceuticals and Industrials Risk Assessment Symposium, sponsored by the Biosafety Institute for Genetically Modified Agricultural Products Symposium, Ames, Iowa, 2004.
350. Wall R, Kerr D, Bondioli K. Transgenic dairy cattle: genetic engineering on a large scale. J. Dairy Sci., 1997; 80: 2213-2224.
351. Masarik M, Kizek R, Kramer KJ, et al. Application of avidin-biotin technology and adsorptive transfer stripping square-wave voltammetry for detection of DNA hybridization and avidin in transgenic avidin maize. Anal. Chem., 2003 ;75(11): 2663-2669.
352. Kramer KJ, Morgan TD, Throne JE, et al. Transgenic avidin maize is resistant to storage insect pests. Nature Biotechnol., 2000 ;18(6): 670-674.
353. Grigorian AV, Shekhter AB, Tolstykh PI, et al. [Proteolytic enzymes in the overall treatment of wounds]. Khirurgiia (Mosk), 1979; (8): 19-23.
354. Yucel VE, Basmajian JV. Decubitus ulcers: healing effect of an enzymatic spray. Arch. Phys. Med. Rehabil., 1974 ;55(11): 517-519.
355. Roep BO, van den Engel NK, van Halteren AG, et al. Modulation of autoimmunity to beta-cell antigens by proteases. Diabetologia, 2002 ;45(5): 686-692.
356. Landis RC, Asimakopoulos G, Poullis M, et al. The antithrombotic and anti-inflammatory mechanisms of action of aprotinin. Ann. Thorac. Surg., 2001 ;72(6): 2169-2175.
357. Landis RC, Haskard DO, Taylor KM. New anti-inflammatory and platelet-preserving effects of aprotinin. Ann. Thorac. Surg., 2001; 72(5): S1808-S1813.
358. Belorgey D, Dirrig S, Amouric M, et al. Inhibition of human pancreatic proteinases by mucus proteinase inhibitor, eglin c and aprotinin. Biochem. J., 1996; 313 (Pt 2): 555-560.
359. Laxenaire MC, Dewachter P, Pecquet C. [Allergic risk of aprotinin]. Ann. Fr. Anesth. Reanim., 2000 ;19(2): 96-104.
360. Barthel T, Kula MR. Studies on the extraction of DesPro(2)-Val15-Leu17-aprotinin from the culture broth of a recombinant Saccharomyces cerevisiae. Bioseparation, 1992 ;3(6): 365-372.
361. GTC Biotherapeutics Reports Second Quarter 2004 Financial Results. http://www.transgenics.com/pressreleases/pr080504.html 2004.
362. Winterbottom N, Kuo J, Nguyen K, et al. Antigenic Responses to Bovine Thrombin Exposure During Surgery: A Prospective Study of 309 Patients. J. Appl. Res. Clin. Exp. Ther., 2002; 2(1).
363. GTC Biotherapeutics Reports Fourth Quarter and Year End 2003 Financial Results. http://www.transgenics.com/pressreleases/pr030304.html 2004.
364. Melcer R. Creve Coeur Startup Develops Human Plasma from Tobacc. St. Louis Post-Dispatch, June 20, 2003.
365. Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax, 2004 ;59(6): 529-535.
366. Chowanadisai W, Huang J, Huang N, et al. Stability of recombinant human alpha-1-antitrypsin produced in rice in infant formula. J. Nutr. Biochem., 2003 ;14(7): 386-393.
367. Flotte TR, Brantly ML, Spencer LT, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum. Gene Ther., 2004 ;15(1): 93-128.
368. Hubbard RC, McElvaney NG, Sellers SE, et al. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. J. Clin. Invest., 1989 ;84(4): 1349-1354.
369. Smerdon GR, Aves SJ, Walton EF. Production of human gastric lipase in the fission yeast Schizosaccharomyces pombe. Gene, 1995 ;165(2): 313-318.
370. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics, 2004; 113(5): e448-e457.
371. Bijvoet AG, Van Hirtum H, Kroos MA, et al. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum. Mol. Genet., 1999 ;8(12): 2145-2153.
372. Bijvoet AG, Kroos MA, Pieper FR, et al. Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum. Mol. Genet., 1998 ;7(11): 1815-1824.
373. Reno J. Performance of corn-seed derived huNR-LU-10. 1998; IBC conference on Transgenic Production, San Francisco, September 1998.
374. Pogue G. Clinical and Pre-Clinical Application of Plant-Derived Glycoproteins. BIO2005 International Conference, San Francisco, 2004.
375. Large Scale Biology and Planet Biotechnology Announce Biomanufacturing Agreement. http://www.lsbc.com/pdfs/Planet-Bio.pdf 2004.
376. Pharming Group 2002 annual report. http://www.pharming.com/downloads/Annual_Report_2002.pdf 2004.
377. van Berkel PH, Welling MM, Geerts M, et al. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nature Biotechnol., 2002 ;20(5): 484-487.
378. Weinberg ED. The therapeutic potential of lactoferrin. Expert Opin. Investig. Drugs, 2003 ;12(5): 841-851.
379. Bethell DR, Huang J. Recombinant human lactoferrin treatment for global health issues: iron deficiency and acute diarrhea. Biometals, 2004 ;17(3): 337-342.
380. Wolf JS, Li D, Taylor RJ, et al. Lactoferrin inhibits growth of malignant tumors of the head and neck. ORL J. Otorhinolaryngol. Relat. Spec., 2003 ;65(5): 245-249.
381. Cornish J, Callon KE, Naot D, et al. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology, 2004 ;145(9): 4366-4374.
382. Huang J, Nandi S, Wu L, et al. Expression of natural antimicrobial human lysozyme in rice grains. Mol. Breeding, 2002; 10(1/2): 83-94.
383. Nandi S, Suzukib Y, Huang J, et al. Expression of human lactoferrin in transgenic rice grains for the application in infant formula. Plant Sci., 2002 ;163(4): 713-722.
384. Sava G. Pharmacological aspects and therapeutic applications of lysozymes. EXS, 1996; 75: 433-449.
385. Brock JH. The physiology of lactoferrin. Biochem. Cell. Biol., 2002 ;80(1): 1-6.
386. Singh PK, Parsek MR, Greenberg EP, et al. A component of innate immunity prevents bacterial biofilm development. Nature, 2002 ;417(6888): 552-555.
387. Markart P, Korfhagen TR, Weaver TE, et al. Mouse lysozyme M is important in pulmonary host defense against Klebsiella pneumoniae infection. Am. J. Respir. Crit. Care Med., 2004 ;169(4): 454-458.
388. A plethora of hi-tech vaccines -genetic, edible, sugar glass, and more. CVI Forum, 1999; (18): 5-23.
389. Arntzen CJ. Edible vaccines. Public Health Rep., 1997 ;112(3): 190-197.
390. Azhar AM, Singh S, Anand KP, et al. Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Biochem. Biophys. Res. Commun., 2002 ;299(3): 345-351.
391. Bonetta L. Edible vaccines: not quite ready for prime time. Nature Med., 2002 ;8(2): 94.
392. Bonn D. Edible vaccines tackle mucosal infections head on. Lancet Infect Dis., 2002 ;2(5): 263.
393. Clough J. Edible vaccines against human papilloma virus. Drug Discov. Today, 2002 ;7(17): 886-887.
394. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci., 2001 ;6(5): 219-226.
395. Fooks AR. Development of oral vaccines for human use. Curr. Opin. Mol. Ther., 2000 ;2(1): 80-86.
396. Keusch GT. The National Institutes of Health agenda for international research in micronutrient nutrition and infection interactions. J. Infect. Dis., 2000; 182 Suppl 1: S139-S142.
397. Lauterslager TG, Hilgers LA. Efficacy of oral administration and oral intake of edible vaccines. Immunol. Lett., 2002 ;84(3): 185-190.
398. Lauterslager TG, Florack DE, van der Wal TJ, et al. Oral immunisation of naive and primed animals with transgenic potato tubers expressing LT-B. Vaccine, 2001; 19(17-19): 2749-2755.
399. Wu YZ, Li JT, Mou ZR, et al. Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA. Virology, 2003 ;313(2): 337-342.
400. Mason HS, Ball JM, Shi JJ, et al. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA, 1996 ;93(11): 5335-5340.
401. Curtiss R, Cardineau G, inventors; Washington University, Mycogen, assignees. Oral immunization by transgenic pl. US Patent US 5, 654, 184; US 5 679880; US 5 686079. 1997.
402. Koga T, Oho T, Shimazaki Y, et al. Immunization against dental caries. Vaccine, 2002 ;20(16): 2027-2044.
403. Ma JK. The caries vaccine: a growing prospect. Dent. Update, 1999 ;26(9): 374-380.
404. Richter LJ, Thanavala Y, Arntzen CJ, et al. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nature Biotechnol., 2000 ;18(11): 1167-1171.
405. Kirk DD, Rempel R, Pinkhasov J, et al. Application of Quillaja saponaria extracts as adjuvants for plant-made vaccines. Expert Opin. Biol. Ther., 2004 ;4(6): 947-958.
406. Kirk DD, Vonhof W, Eibner J, et al. Model Production of a Potent Plant-Made Vaccin. NFID Sixth Annual Conference on Vaccine Research, 5-8 May, Arlington, VA, 2003.
407. Tacket CO, Mason HS, Losonsky G, et al. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature Med., 1998 ;4(5): 607-609.
408. Mason HS, Haq TA, Clements JD, et al. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine, 1998 ;16(13): 1336-1343.
409. Lam D, Arntzen C, Mason H, inventors; ProdiGene, assignee. Vaccines expressed in plants. US Patent US 6034298. 2000.
410. Stiefelhagen P. [Oral vaccines -a future prospect! Hepatitis vaccination in the vegetable market?]. MMW Fortschr. Med., 2003 ;145(47): 10.
411. Smith ML, Mason HS, Shuler ML. Hepatitis B surface antigen (HBsAg) expression in plant cell culture: Kinetics of antigen accumulation in batch culture and its intracellular form. Biotechnol. Bioeng., 2002 ;80(7): 812-822.
412. Smith ML, Keegan ME, Mason HS, et al. Factors important in the extraction, stability and in vitro assembly of the hepatitis B surface antigen derived from recombinant plant systems. Biotechnol. Prog., 2002 ;18(3): 538-550.
413. Thanavala Y, Yang YF, Lyons P, et al. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA, 1995 ;92(8): 3358-3361.
414. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. USA, 1992 ;89(24): 11745-11749.
415. Edible vaccines for Helicobacter pylori and rotaviruses: Deprohealth project. http://www.flair-flow.com/consumer-docs/ffe63503.html 2004.
416. Nakata S. [Vaccine development for Norwalk virus]. Nippon Rinsho, 2002 ;60(6): 1222-1227.
417. Koprowski H. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants]. Arch. Immunol. Ther. Exp. (Warsz), 2002 ;50(6): 365-369.
418. Bosch X. Tobacco fights back. Lancet Oncol., 2004 ;5(5): 264.
419. Varsani A, Williamson AL, Rose RC, et al. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch. Virol., 2003 ;148(9): 1771-1786.
420. Dow enters NIH research agreement to develop rapid vaccine production system. http://www.fraunhofer-cmb.org/index.cfm? act=news 2004.
421. Hood EE, Jilka JM. Plant-based production of xenogenic proteins. Curr. Opin. Biotechnol., 1999 ;10(4): 382-386.
422. Walmsley AM, Arntzen CJ. Plants for delivery of edible vaccines. Curr. Opin. Biotechnol., 2000 ;11(2): 126-129.
423. Touchette N. New Company to Make Drugs from Plants. GNN News Alerts 2003.
424. Beck E. Researchers at Thomas Jefferson University developed a way to make a safer anthrax vaccin. United Press International. March 12, 2003.
425. Huang JK, Li M. [Silk protein fiber biomaterials and tissue engineering]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2004 ;18(2): 127-130.
426. Williams D. Sows' ears, silk purses and goats' milk: new production methods and medical applications for silk. Med. Device Technol., 2003 ;14(5): 9-11.
427. Prunkard D, Cottingham I, Garner I, et al. High-level expression of recombinant human fibrinogen in the milk of transgenic mice. Nature Biotechnol., 1996 ;14(7): 867-871.
428. Toman PD, Pieper F, Sakai N, et al. Production of recombinant human type I procollagen homotrimer in the mammary gland of transgenic mice. Transgenic Res., 1999 ;8(6): 415-427.
429. John DC, Watson R, Kind AJ, et al. Expression of an engineered form of recombinant procollagen in mouse milk. Nature Biotechnol., 1999 ;17(4): 385-389.
430. Tomita M, Munetsuna H, Sato T, et al. Transgenic silkworms produce recombinant human type III procollagen in cocoons. Nature Biotechnol., 2003 ;21(1): 52-56.
431. Ruggiero F, Chanut H, Fichard A. Production of Recombinant Collagen for Biomedical Devices. BioPharm, 2000; 32-37.
432. Bellingham CM, Lillie MA, Gosline JM, et al. Recombinant human elastin polypeptides self-assemble into biomaterials with elastinlike properties. Biopolymers, 2003 ;70(4): 445-455.
433. Bellingham CM, Woodhouse KA, Robson P, et al. Self-aggregation characteristics of recombinantly expressed human elastin polypeptides. Biochim. Biophys. Acta, 2001 ;1550(1): 6-19.
434. Keeley FW, Bellingham CM, Woodhouse KA. Elastin as a self-organizing biomaterial: use of recombinantly expressed human elastin polypeptides as a model for investigations of structure and self-assembly of elastin. Philos. Trans. R. Soc. Lond. B Biol. Sci., 2002 ;357(1418): 185-189.
435. Woodhouse KA, Klement P, Chen V, et al. Investigation of recombinant human elastin polypeptides as non-thrombogenic coatings. Biomaterials, 2004 ;25(19): 4543-4553.
436. Yang G, Woodhouse KA, Yip CM. Substratefacilitated assembly of elastin-like peptides: studies by variable-temperature in situ atomic force microscopy. J. Am. Chem. Soc., 2002 ;124(36): 10648-10649.
437. Bucchini L, Goldman LR. Starlink corn: a risk analysis. Environ. Health Perspect., 2002 ;110(1): 5-13.
438. Benowitz S. Jefferson Scientistis Create Plant Factories churning out Antibodies against Tumor Cells (Press Release. Jefferson University Hospital, Philadelphia, May 3, 2005.